Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Other · France
Declared costs: €25K+ a year · in the register since 2018
Industry association · Belgium
Declared costs: €6M+ a year · in the register since 2009
European Biotech Act · Compulsory licensing of patents in crisis situations · Supplementary protection certificate for plant protection products. Recast
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
CNCPI · filed 11 Jun 2025 · source
Compagnie nationale des agents en propriété industrielle (CNCPI) is the French official body comprising all industrial property agents, namely the liberal professionals specialising in industrial property operating in France. In the context of the public consultation on the European Biotech Act, the CNCPI wishes to bring the attached position paper to the attention of the European Commission.
Filed in French · English published by the European Commission
EFPIA · filed 11 Jun 2025 · source
EFPIA strongly support the ambition to foster a world-class innovation environment for biotechnologies.To make the EU more attractive for researching, developing and manufacturing new technologies,we urge coordinated and urgent action across several areas.
EFPIA · filed 22 Jul 2026 · source
EFPIA welcomes the European Commission's initiative to develop the Biotech Act and strongly supports its objective of strengthening Europe's life sciences ecosystem. Europe has world-class scientific capabilities and a strong industrial base but continues to face challenges in translating research excellence into investment, clinical development, manufacturing and patient access.
EFPIA · filed 22 Jul 2026 · source
EFPIA welcomes the European Commission's initiative to develop the Biotech Act and strongly supports its objective of strengthening Europe's life sciences ecosystem. Europe has world-class scientific capabilities and a strong industrial base but continues to face challenges in translating research excellence into investment, clinical development, manufacturing and patient access.
EFPIA · filed 28 Apr 2022 · source
The substantial investment in R&D by multiple actors over many years into novel technologies, vaccine, therapeutic and other products now available to address Covid-19 would not have occurred without the robust IP system in the EU and elsewhere. IP protections, particularly patents, has provided the legal framework and incentive for the high risk, high-cost investment underpinning the response to the pandemic.
CNCPI · filed 29 Apr 2022 · source
The CNCPI, a body set up by the French Intellectual Property Code and representing the regulated liberal profession of all French patent agents, thanked the European Commission for the opportunity to participate in this call for contributions and welcomed its willingness to consult with a view to possible legislative work on compulsory patent licences.
Filed in French · English published by the European Commission
EFPIA · filed 28 Jul 2023 · source
In its Compulsory Licensing (CL) proposal, the European Commission (EC) posits a new EU-wide CL for crisis response. This harms IP rights and is a dramatic expansion of the ECs role into Member State (MS) remit, where viable CL provisions already exist. CLs are a last resort, all attempts at voluntary licensing having failed.
EFPIA · filed 30 Mar 2022 · source
Bringing new therapies to patients is a long, complex and risky process that requires long-term and continuous investments. Patents are critical to that purpose and to the EU’s innovation and industrial ambitions.
CNCPI · filed 5 Apr 2022 · source
The CNCPI, a body representing the regulated liberal profession comprising all French patent agents, thanks the European Commission for the opportunity to participate in this call for contributions and welcomes its desire to review the system for granting supplementary protection certificates (SPCs).
Filed in French · English published by the European Commission
EFPIA · filed 15 Sept 2023 · source
EFPIA supports the stated aims for the SPC revisions. Central SPC issuance for classical European patents and Unitary Patents will improve IP framework efficiency, bringing innovative medicines to patients in a timely manner via reliable protection.
EFPIA · filed 15 Sept 2023 · source
EFPIA supports the stated aims for the SPC revisions. Central SPC issuance for classical European patents and Unitary Patents will improve IP framework efficiency, bringing innovative medicines to patients in a timely manner via reliable protection.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.